MedWatch

With six treatments in the clinical phase, Leo Pharma can look forward to another heavy year for development

In 2020, Leo Pharma is rearming itself in order to massively increase the research and development budget. The aim is to accelerate the development of new drugs, including the company's big hope: eczema drug tralokinumab.

Foto: Leo Pharma/PR

Although biological eczema drug tralokinumab seems to get all of the attention, Leo Pharma has five other drugs in its clinical development pipeline.

The company is transitioning from being a firm that focuses on traditional, topical treatments to one that focuses on innovative dermatology treatments. This has been an expensive task for Leo Pharma so far, and will continue to be so in 2020.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

CHMP blåstempler ni nye lægemidler i maj

Den europæiske lægemiddelkomite, CHMP, har på dets møde i maj indstillet ni nye lægemidler til godkendelse samt anbefalet, at seks midler kan tages i brug på nye måder. To midler afvist.

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier